Vertiflex’s Superion Interspinous Spacer Gets FDA Panel Date
This article was originally published in The Gray Sheet
FDA’s Orthopaedic and Rehabilitation Devices Panel will meet in December to consider Vertiflex’s submission to support approval of the Superion interspinous spacer to treat moderate lumbar spinal stenosis.
You may also be interested in...
In less than a month, the US Food and Drug Administration (FDA) recently approved three spine PMAs, two for cervical disc replacement devices, and there are two more cervical discs in the queue for near-term PMA approval. All of this activity suggests the $122 million US cervical disc market is about to gear up.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.